VENLOR
Mood Disorders
Otsuka Pharmaceutical Development & Commercialization, Inc.Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Mood Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Seroquel® First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
Opc-34712 Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | BBB |
Arestin Pakistan Institute of Living and Learning | Phase 4 | BBB |
FLUOXETINE University of Ghana Medical School | Phase 4 | BBB |
Olanzapine University of Ghana Medical School | Phase 4 | BBB |
View all 36 →
Same molecule, other indications
VENLOR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →